These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38868222)

  • 1. Multiomics characterization and verification of clear cell renal cell carcinoma molecular subtypes to guide precise chemotherapy and immunotherapy.
    Meng J; Jiang A; Lu X; Gu D; Ge Q; Bai S; Zhou Y; Zhou J; Hao Z; Yan F; Wang L; Wang H; Du J; Liang C
    Imeta; 2023 Nov; 2(4):e147. PubMed ID: 38868222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MOICS, a novel classier deciphering immune heterogeneity and aid precise management of clear cell renal cell carcinoma at multiomics level.
    Liu Y; Qi L; Ye B; Wang A; Lu J; Qu L; Luo P; Wang L; Jiang A
    Cancer Biol Ther; 2024 Dec; 25(1):2345977. PubMed ID: 38659199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new thinking: extended application of genomic selection to screen multiomics data for development of novel hypoxia-immune biomarkers and target therapy of clear cell renal cell carcinoma.
    Gui CP; Wei JH; Chen YH; Fu LM; Tang YM; Cao JZ; Chen W; Luo JH
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34237133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crosstalk Between Metabolism and Immune Activity Reveals Four Subtypes With Therapeutic Implications in Clear Cell Renal Cell Carcinoma.
    Wang Y; Zheng XD; Zhu GQ; Li N; Zhou CW; Yang C; Zeng MS
    Front Immunol; 2022; 13():861328. PubMed ID: 35479084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlating Immune Cell Infiltration Patterns with Recurrent Somatic Mutations in Advanced Clear Cell Renal Cell Carcinoma.
    Chakiryan NH; Hajiran A; Kim Y; Aydin AM; Zemp L; Katende E; Nguyen J; Fan W; Cheng CH; Lopez-Blanco N; Chahoud J; Spiess PE; Fournier M; Dhillon J; Wang L; Moran-Segura C; Mulé J; Du D; Yoder SJ; Berglund A; Teer JK; Manley BJ
    Eur Urol Focus; 2022 May; 8(3):784-793. PubMed ID: 33994165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SPCS, a Novel Classifier System Based on Senescence Axis Regulators Reveals Tumor Microenvironment Heterogeneity and Guides Frontline Therapy for Clear Cell Renal Carcinoma.
    Jiang A; Liu Y; Zhu B; Fang Y; Qu L; Yang Q; Luo P; Cai C; Wang L
    Clin Genitourin Cancer; 2024 Apr; 22(2):497-513. PubMed ID: 38245436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Subtypes Based on Genomic and Transcriptomic Features Correlate with the Responsiveness to Immune Checkpoint Inhibitors in Metastatic Clear Cell Renal Cell Carcinoma.
    Jee B; Seo E; Park K; Kim YR; Byeon SJ; Lee SM; Chung JH; Song W; Sung HH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Park SH; Park WY; Kang M
    Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35625960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutrophil extracellular traps-associated modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of clear cell renal cell carcinoma.
    Teng ZH; Li WC; Li ZC; Wang YX; Han ZW; Zhang YP
    Front Oncol; 2022; 12():1094248. PubMed ID: 36620592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
    Büttner FA; Winter S; Stühler V; Rausch S; Hennenlotter J; Füssel S; Zastrow S; Meinhardt M; Toma M; Jerónimo C; Henrique R; Miranda-Gonçalves V; Kröger N; Ribback S; Hartmann A; Agaimy A; Stöhr C; Polifka I; Fend F; Scharpf M; Comperat E; Wasinger G; Moch H; Stenzl A; Gerlinger M; Bedke J; Schwab M; Schaeffeler E
    Genome Med; 2022 Sep; 14(1):105. PubMed ID: 36109798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of Molecular Heterogeneity Associated With Tumor Microenvironment in Clear Cell Renal Cell Carcinoma to Aid Immunotherapy.
    Zhong W; Li Y; Yuan Y; Zhong H; Huang C; Huang J; Lin Y; Huang J
    Front Cell Dev Biol; 2021; 9():736540. PubMed ID: 34631713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An integrative genomics approach for identifying novel functional consequences of PBRM1 truncated mutations in clear cell renal cell carcinoma (ccRCC).
    Wang Y; Guo X; Bray MJ; Ding Z; Zhao Z
    BMC Genomics; 2016 Aug; 17 Suppl 7(Suppl 7):515. PubMed ID: 27556922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-omics analysis uncovers clinical, immunological, and pharmacogenomic implications of cuproptosis in clear cell renal cell carcinoma.
    Zhu M; Li Y; Wang Y; Lin P; Mi J; Zhong W
    Eur J Med Res; 2023 Jul; 28(1):248. PubMed ID: 37481601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a claudin-low subtype in clear cell renal cell carcinoma with implications for the evaluation of clinical outcomes and treatment efficacy.
    Zhang C; Li Y; Qian J; Zhu Z; Huang C; He Z; Zhou L; Gong Y
    Front Immunol; 2022; 13():1020729. PubMed ID: 36479115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Definition and verification of novel metastasis and recurrence related signatures of ccRCC: A multicohort study.
    Jiang A; Pang Q; Gan X; Wang A; Wu Z; Liu B; Luo P; Qu L; Wang L
    Cancer Innov; 2022 Aug; 1(2):146-167. PubMed ID: 38090653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor microenvironment immune subtypes for classification of novel clear cell renal cell carcinoma profiles with prognostic and therapeutic implications.
    Wang Q; Hu J; Kang W; Wang J; Xiang Y; Fu M; Gao H; Huang Z
    Medicine (Baltimore); 2021 Mar; 100(11):e24949. PubMed ID: 33725966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of Hypoxia-Related Molecular Subtypes in Clear Cell Renal Cell Carcinoma to Aid Immunotherapy and Targeted Therapy
    Zhong W; Zhong H; Zhang F; Huang C; Lin Y; Huang J
    Front Mol Biosci; 2021; 8():684050. PubMed ID: 34250018
    [No Abstract]   [Full Text] [Related]  

  • 17. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.
    Hsieh JJ; Chen D; Wang PI; Marker M; Redzematovic A; Chen YB; Selcuklu SD; Weinhold N; Bouvier N; Huberman KH; Bhanot U; Chevinsky MS; Patel P; Pinciroli P; Won HH; You D; Viale A; Lee W; Hakimi AA; Berger MF; Socci ND; Cheng EH; Knox J; Voss MH; Voi M; Motzer RJ
    Eur Urol; 2017 Mar; 71(3):405-414. PubMed ID: 27751729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deciphering the Role of Melatonin-Related Signatures in Tumor Immunity and the Prognosis of Clear Cell Renal Cell Carcinoma.
    Jiang A; Cai C; Yang Y; Cui Y; Liu W; Pang Q; Wu Z; Liu B; Qu L; Luo P; Wang A; Wang L
    Oxid Med Cell Longev; 2023; 2023():3077091. PubMed ID: 36825082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of immune subtypes to guide immunotherapy and targeted therapy in clear cell renal cell carcinoma.
    Xu C; Li Y; Su W; Wang Z; Ma Z; Zhou L; Zhou Y; Chen J; Jiang M; Liu M
    Aging (Albany NY); 2022 Sep; 14(17):6917-6935. PubMed ID: 36057262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of molecular subtypes and diagnostic model in clear cell renal cell carcinoma based on collagen-related genes may predict the response of immunotherapy.
    Hong Y; Lv Z; Xing Z; Xu H; Chand H; Wang J; Li Y
    Front Pharmacol; 2024; 15():1325447. PubMed ID: 38375034
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.